- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04784507
En-Bloc Resection of Bladder Tumors
En-Bloc Resection of Bladder Tumors: a Multicentric Safety and Feasibility Trial (IDEAL Phase II) vs Conventional Resection of Bladder Tumors?
Observational data shows that "en bloc" resection of bladder tumor (EBR-BT) may entail advantages when compared with conventional transurethral bladder tumor resection (TURBT). EBR-BT has the potential to increase the rate of correct staging and accurate assignment of risk-classification in non-muscle-invasive bladder cancer (NMIBC) and to avoid re-TURBT in a considerable number of high-grade NMIBC by demonstrating total macro and microscopic eradication of the primary tumor and to provide the basis for a correct treatment based on a correct stage.
Following the rules of the IDEAL collaboration evaluation and stages of surgical innovation and considering EBR-BT as a surgical technical innovation, the investigators designed a multi-institutional, stage 2a/b study on feasibility (procedural success), safety (including pathology features), and short-term efficacy of EBR-BT and as proof of concept on the reliability of NMIBC staging.
Main objective: to prospectively assess the pathological efficacy of EBR-BT in the staging of bladder cancer and the clinical efficacy at short-term recurrence-free survival.
Secondary objectives: To assess the clinical efficacy at short-term (3-months) of EBR-BT, and to compare efficacy in the staging of the EBR-BT with the conventional TURBT.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
En-bloc resection of bladder tumors (EBR-BT) has been showing certain advantages over conventional transurethral resection technique (TURBT) in non-muscle-invasive bladder cancer. These advantages consist mainly in the reduction of obturator nerve reflex and obtention of surgical samples according to oncological principles. Advantages in terms of tumor recurrence in the short-term, when compared with TURBT, remain uncertain. Herein several randomized control trials aim to assess comparative outcomes in the short and long term.
A higher rate of detrusor muscle is found in the EBR-BT samples than in the conventional samples resulting in a better staging and at least theoretically the need for fewer re-TURBT indications. However, a detailed and scrupulous description of the histopathological samples is lacking and, it is assumed that the presence of detrusor in the sample without solution of continuity with submucosa and tumor is sufficient to stage. As in surgical samples of other organs, the objective of EBR-RT is not only to obtain detrusor, but also clean margins that ensure the radicality of the tumor.
The hypothesis of the investigators' is that EBR-BT will results in an increased rate of pathological specimen with the presence of detrusor muscle and free-tumor margins, hence a more accurate stage than TURBT and a decrease in 3-months recurrence at short-term (3 months)
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Rahim Horuz
- Phone Number: +90533 934 38 50
- Email: rhoruz@medipol.edu.tr
Study Contact Backup
- Name: Betul Kartal
- Email: bbkartal@medipol.edu.tr
Study Locations
-
-
Bagcilar
-
Istanbul, Bagcilar, Turkey, 34200
- Recruiting
- Bagcilar Education and Research Hospital
-
Contact:
- Bagcilar
- Phone Number: (0212) 440 40 00
-
Istanbul, Bagcilar, Turkey, 34214
- Recruiting
- Medipol Mega University Hospital
-
Contact:
- Medipol
- Phone Number: 444 7 044
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18 years old and older (adult, older adult) Sexes: All Accepts healthy volunteers: No
Inclusion criteria:
- Patients aged 18 and older presenting with suspicion of primary or recurrent Non-muscle invasive bladder cancer (NMIBC)
- Tumor size estimated by cystoscopy ≤ 3 cm
- Solitary or multiple tumors (up to 3 in number)
Exclusion Criteria:
- Tumor size > 3 cm of maximum dimeter
- Patient with severe systemic disease (ASA III+)
- Location on the anterior bladder wall and/ or anterior bladder neck (relative contraindication depending on accessibility)
- Pregnancy
- Histological diagnosis other than NMIBC urothelial bladder cancer
- Presence or history of previous upper-tract urinary cancer (UTUC)
- Presence of positive cytology without macroscopic identifiable bladder tumor
- Life expectancy < 1 year
- Non-reversible coagulopathy
- Bladder tumor detected during intravesical BCG therapy
- Tumor multiplicity (> 3 tumors)
Contacts and locations:
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: En Bloc Resection Bladder Tumor (Any energy source)
Patients with suspicion of NMIBC (primary or recurrent) that underwent en bloc resection (EBRT
|
En bloc transurethral resection of bladder tumor (EBR-BT) using any energy source (laser and bipolar or monopolar energy)
|
Active Comparator: Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)
Patients with suspicion of NMIBC (primary or recurrent) that underwent conventional TURBT
|
Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological Staging
Time Frame: Immediately after the intervention
|
Staging of NMIBC is defined by the presence of sufficient detrusor in the EBR-BT specimens, the status of the margins, presence of a tumor and /or CIS in the mucosal margins, the status of the detrusor margin, and suspicion of instability in mucosa free of tumor.
|
Immediately after the intervention
|
Recurrence at 3 months
Time Frame: 3 months
|
Recurrence free survival at 3-months (absence of visible tumors at the site of the previous resection
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Operative Complications
Time Frame: intraoperative
|
Rate of operative complications (estimated bleeding, bladder perforation, obturatory reflex, tumor fragmentation, conversion to conventional TURBT)
|
intraoperative
|
Perioperative Complications
Time Frame: Up to 90 days
|
Postoperative complications according to Clavien-Dindo classification
|
Up to 90 days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10840098-604.01.01-E.55105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Neoplasm
-
Ikena OncologyBristol-Myers SquibbCompletedNeoplasms | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Bladder Cancer | Advanced Solid Tumor | Advanced Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | Bladder Disease | Solid Carcinoma | Neoplasm Malignant | Neoplasm, Bladder | Locally Advanced... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Astellas Pharma Inc; Seagen...RecruitingStage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Metastatic Bladder Carcinoma | Urachal Adenocarcinoma | Locally Advanced Bladder Carcinoma | Malignant Renal Pelvis Neoplasm | Malignant Ureter Neoplasm | Malignant Urethral Neoplasm and other conditionsUnited States
-
Abdelwahab HashemUnknownTrauma | Bladder Cancer | Injuries | Bladder Urothelial Carcinoma | Perforation of Bladder | Recurrence Tumor | Resection Margin | Seeding, NeoplasmEgypt
-
Mansoura UniversityCompletedBladder Cancer | Bladder Disease | Bladder Neoplasm | Micro-RNAEgypt
-
Benha UniversityRecruiting
-
Diskapi Teaching and Research HospitalCompleted
-
Ziv HospitalNot yet recruitingBladder Neoplasm
-
Nektar TherapeuticsBristol-Myers SquibbCompletedNeoplasm Metastasis | Urinary Bladder NeoplasmUnited States, Spain, United Kingdom, Belgium, Canada, Australia, France, Italy, Greece, Germany, Portugal, Argentina, Israel, Russian Federation, Turkey, Mexico, Finland, Netherlands
-
GlaxoSmithKlineCompletedNeoplasms, Urinary BladderBelgium
-
Ziv HospitalAzrieli Faculty of medicine, Bar Ilan University, Safed, ILNot yet recruitingBladder Neoplasm
Clinical Trials on En Bloc Resection
-
Tongji HospitalUnknownNon-muscle Invasive Bladder Cancer
-
Mansoura UniversityUnknown
-
Jørgen Bjerggaard JensenNovo Nordisk A/S; University of AarhusRecruitingNon-muscle Invasive Bladder CancerDenmark, Norway, Latvia
-
University of Sao PauloCAIO SERGIO NAHAS; SERGIO CARLOS NAHAS; Ivan Cecconello; Ulysses Ribeiro Junior; Carlos... and other collaboratorsCompleted
-
University of Kansas Medical CenterRecruitingSurgery | Bladder CancerUnited States
-
Chinese University of Hong KongAgilis Robotics LimitedNot yet recruiting
-
Chinese University of Hong KongRecruiting
-
Chinese University of Hong KongThe University of Hong Kong; Queen Elizabeth Hospital, Hong Kong; North District... and other collaboratorsCompleted
-
I.M. Sechenov First Moscow State Medical UniversityUnknownBladder CancerRussian Federation
-
Chinese University of Hong KongRecruitingBladder Cancer | Bladder Tumor | Bladder NeoplasmHong Kong